Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience

D Loli-Ausejo; G Perdomo; B Mascaró; P Martínez-Olondris; M C Sánchez-Fernández; J Mullol; A Valero; E Arismendi; I Bobolea

doi:10.18176/jiaci.0898

Mepolizumab for Treatment of Severe Eosinophilic Asthma: A 5-Year Real-World Experience

J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):209-210. doi: 10.18176/jiaci.0898. Epub 2023 Feb 23.

Authors

D Loli-Ausejo^{1

2}, G Perdomo³, B Mascaró^{1

2}, P Martínez-Olondris^{2

4}, M C Sánchez-Fernández¹, J Mullol^{2

5

6

7}, A Valero^{1

2

6

7}, E Arismendi^{2

4

6

7}, I Bobolea^{1

2

6

7}

Affiliations

¹ Department of Allergy, Hospital Clínic Barcelona, Barcelona, Spain.
² Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.
³ Department of Allergy, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
⁴ Department of Pneumology, Hospital Clínic Barcelona, Barcelona, Spain.
⁵ Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, Barcelona, Spain.
⁶ University of Barcelona, Barcelona, Spain.
⁷ CIBER of Respiratory Diseases (CIBERES), Health Institute Carlos III.

PMID: 36820628
DOI: 10.18176/jiaci.0898

No abstract available

Keywords: Asthma; Mepolizumab; Monoclonal antibodies; Severe eosinophilic asthma; Treatment.

MeSH terms

Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Humans
Pulmonary Eosinophilia* / drug therapy
Treatment Outcome

Substances

mepolizumab
Antibodies, Monoclonal, Humanized
Anti-Asthmatic Agents